Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

We thank all patients who participated in the MajesTEC-1 and LocoMMotion studies and the families and caregivers, physicians, and nurses who cared for the patients and supported the studies. We also thank the staff members at the MajesTEC-1 and LocoMMotion sites involved in data collection, data analysis, and interpretation, and acknowledge the contributions of Nichola Erler-Yates and Jedelyn Cabrieto (Janssen) to the data analyses.

Funding

Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. MajesTEC-1 was funded by Janssen Research & Development, LLC. LocoMMotion was funded by Janssen Research & Development, LLC and Legend Biotech, Inc. Funding for the publication of this study, including the journal’s Rapid Service and Open Access fees were provided by Janssen Global Services, LLC.

Medical Writing, Editorial, and Other Assistance

Medical writing support was provided by John Bilbruck, PhD, and Linda Wychowski, PhD, of Eloquent Scientific Solutions, and funded by Janssen Global Services, LLC.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Author Contributions

Philippe Moreau, Aurore Perrot, Rachel Kobos, Jennifer Smit, and Maria-Victoria Mateos: Conceptualization, Investigation, Visualization, Writing-Reviewing and Editing Niels W. C. J. van de Donk, Michel Delforge, Hermann Einsele, Valerio De Stefano, Britta Besemer, Charlotte Pawlyn, Lionel Karlin, Salomon Manier, Xavier Leleu, Katja Weisel, and Ahmed Elsada: Conceptualization, Investigation, Writing-Reviewing and Editing Francesca Ghilotti: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing original draft, Writing-Reviewing and Editing Joris Diels: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Supervision, Visualization, Writing original draft, Writing-Reviewing and Editing Raul Morano and Mary Slavcev: Conceptualization, Investigation, Methodology, Project administration, Supervision, Writing-Reviewing and Editing Vadim Strulev: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision, Visualization, Writing original draft, Writing-Reviewing and Editing Lixia Pei: Conceptualization, Investigation, Methodology, Writing-Reviewing and Editing.

Prior Presentation

This manuscript is based on work that was previously presented at the 2022 American Society of Clinical Oncology Annual Meeting; June 3–7, 2022; Chicago, IL, USA and online. Niels W.C.J van de Donk, et al. Comparative efficacy of teclistamab (tec) versus current treatments (tx) in real-world clinical practice in the prospective LocoMMotion study in patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 40, 2022 (suppl 16; abstr 8016).

Disclosures

Philippe Moreau has held a consulting or advisory role for AbbVie, Amgen, Celgene, GlaxoSmithKline, Janssen, Oncopeptides, and Sanofi; and received honoraria from AbbVie, Amgen, Celgene, GlaxoSmithKline, Janssen-Cilag, Oncopeptides, and Sanofi. Niels W. C. J. van de Donk has received honoraria from Celgene; held a consulting or advisory role for Amgen, Bayer, Celgene, Janssen, Novartis, Roche, Servier, and Takeda; and received research funding from Amgen, BMS, Cellectis, and Janssen. Michel Delforge has held a consulting or advisory role for Amgen, Celgene, and Janssen; and received honoraria from Amgen, Celgene, and Janssen. Hermann Einsele has held a consulting or advisory role for Amgen, Bristol Myers Squibb, Celgene, Janssen, Novartis, and Takeda; received travel, accommodations, and/or expenses from Amgen, Bristol Myers Squibb, Celgene, Janssen, and Takeda; received honoraria from Amgen, Bristol Myers Squibb, Celgene, Janssen, Novartis, and Takeda; and received research funding from Amgen, Bristol Myers Squibb, Celgene, and Janssen. Valerio De Stefano has received honoraria from AbbVie, Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi, and Takeda. Aurore Perrot has received honoraria from AbbVie, Amgen, Celgene, Janssen-Cilag, GlaxoSmithKline, Sanofi, and Takeda. Britta Besemer has received travel, accommodations, and/or expenses from Janssen-Cilag; and received honoraria from Janssen-Cilag. Charlotte Pawlyn has received honoraria from Amgen, Celgene/Bristol Myers Squibb, Janssen, Sanofi, and Takeda. Lionel Karlin reports employment (family member) by Aguettant; has received honoraria from AbbVie, Amgen, Celgene/Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi, and Takeda; has held a consulting or advisory role for AbbVie, Amgen, Celgene/Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi, and Takeda; and has received travel, accommodations, and/or expenses from Amgen, Janssen, Sanofi, and Takeda. Salomon Manier has received research funding from AbbVie, Celgene/Bristol Myers Squibb, Janssen, Novartis, and Takeda. Xavier Leleu has held a consulting or advisory role for AbbVie, Amgen, Bristol Myers Squibb, CARsgen Therapeutics, Celgene, Gilead Sciences, GlaxoSmithKline, Janssen-Cilag, Karyopharm Therapeutics, Merck, Novartis, Oncopeptides, Roche, and Takeda; received travel, accommodations, and/or expenses from Takeda; and received honoraria from AbbVie, Amgen, Bristol Myers Squibb, CARsgen Therapeutics, Celgene, GlaxoSmithKline, Janssen-Cilag, Karyopharm Therapeutics, Merck, Novartis, Oncopeptides, Roche, Sanofi, and Takeda. Katja Weisel has held a consulting or advisory role for Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen-Cilag, Karyopharm Therapeutics, Oncopeptides, Roche, Sanofi, and Takeda; has received travel, accommodations, and/or expenses from Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen-Cilag, and Takeda; received honoraria from AbbVie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen-Cilag, Karyopharm Therapeutics, Novartis, Oncopeptides, Pfizer, Roche/Genentech, Sanofi, and Takeda; and has received research funding from Amgen, Bristol Myers Squibb/Celgene, Celgene, GlaxoSmithKline, Janssen-Cilag, and Sanofi. Francesca Ghilotti is employed by Janssen. Joris Diels is employed by and has stock/other ownership interests in Janssen. Ahmed Elsada was employed by Janssen-Cilag during the conduct of the research and publication development; he is currently an employee of Bristol-Myers Squibb. Raul Morano is employed by Janssen. Vadim Strulev is employed by and has stock/other ownership interests in Janssen. Lixia Pei is employed by and has stock/other ownership interests in Janssen. Rachel Kobos is employed by and has stock/other ownership interests in Janssen. Jennifer Smit is employed by, has stock/other ownership interests in, and has received travel, accommodations, and/or expenses from Johnson & Johnson/Janssen. Mary Slavcev is employed by and has stock/other ownership interests in Janssen. Maria-Victoria Mateos has held a consulting or advisory role for AbbVie, Amgen, Celgene, GlaxoSmithKline, Janssen-Cilag, Pfizer, Regeneron, Roche/Genentech, and Takeda; and received honoraria from AbbVie/Genentech, Amgen, Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi, and Takeda.

Compliance With Ethics Guidelines

Data analyzed in this study were received from the MajesTEC-1 and LocoMMotion studies. MajesTEC-1 was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Guidelines for Good Clinical Practice. All patients provided written informed consent. An independent ethics committee or institutional review board at each study center approved the study protocol. The LocoMMotion study was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent. An independent ethics committee/institutional review board at each center approved the study protocol.

Data Availability

Data used for this study were based on the MajesTEC-1 and LocoMMotion studies. MajesTEC-1 data sharing is governed by the Janssen Pharmaceutical Companies of Johnson & Johnson data sharing policy that is available online. As noted on policy, requests for access to the study data can be submitted through Yale Open Data.

留言 (0)

沒有登入
gif